Fifth Third Bancorp Has $106,000 Holdings in Halozyme Therapeutics, Inc. $HALO

Fifth Third Bancorp cut its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 86.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,582 shares of the biopharmaceutical company’s stock after selling 9,916 shares during the quarter. Fifth Third Bancorp’s holdings in Halozyme Therapeutics were worth $106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Sigma Planning Corp grew its stake in Halozyme Therapeutics by 22.2% in the 4th quarter. Sigma Planning Corp now owns 9,592 shares of the biopharmaceutical company’s stock valued at $646,000 after buying an additional 1,741 shares during the last quarter. New York State Teachers Retirement System grew its position in Halozyme Therapeutics by 0.7% in the 4th quarter. New York State Teachers Retirement System now owns 125,968 shares of the biopharmaceutical company’s stock worth $8,478,000 after purchasing an additional 853 shares during the last quarter. Verity Asset Management Inc. grew its position in Halozyme Therapeutics by 11.6% in the 4th quarter. Verity Asset Management Inc. now owns 53,118 shares of the biopharmaceutical company’s stock worth $3,575,000 after purchasing an additional 5,506 shares during the last quarter. Cardinal Capital Management grew its position in Halozyme Therapeutics by 5.2% in the 4th quarter. Cardinal Capital Management now owns 18,689 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 921 shares during the last quarter. Finally, Torren Management LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter worth $88,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 1.6%

Shares of HALO stock opened at $64.12 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a market capitalization of $7.60 billion, a P/E ratio of 25.75, a P/E/G ratio of 0.27 and a beta of 0.89. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The firm has a 50-day moving average price of $65.86 and a 200 day moving average price of $68.59.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. During the same period in the prior year, the firm posted $1.26 earnings per share. The company’s revenue was up 51.6% on a year-over-year basis. Research analysts forecast that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on HALO. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Benchmark raised their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $79.11.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the completion of the transaction, the chief operating officer directly owned 14,366 shares of the company’s stock, valued at approximately $974,014.80. This represents a 58.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 90,482 shares of company stock valued at $6,073,942. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.